Zymeworks (ZYME)

• Market cap: $1.14B
• 1 day: -3.51%
• 5 days: 4.07%
• 1 month: 9.30%
• 3 months: 29.86%
• 6 months: 7.37%
• Year to date: -1.42%
• 1 year: 26.26%
• 5 years: -56.62%
• 10 years: 12.08%
• Sector: Healthcare
• Industry: Biotechnology

About: Zymeworks Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics. Its suite of therapeutic platforms and its fully integrated drug development engine enables precise engineering of differentiated therapeutic product candidates. Its clinical candidate, zanidatamab, is a novel HER2-targeted bispecific antibody currently being evaluated in multiple Phase 1, Phase 2, and pivotal clinical trials globally as a targeted treatment option for patients with solid tumors that express HER2. The company is also advancing a deep preclinical pipeline in oncology and other therapeutic areas.

Employees: 273

Fund manager confidence

Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)

1,510% more call options, than puts

Call options by funds: $3.35M | Put options by funds: $208K

15% more repeat investments, than reductions

Existing positions increased: 61 | Existing positions reduced: 53

12% more capital invested

Capital invested by funds: $839M [Q1] → $942M (+$103M) [Q2]

6.69% more ownership

Funds ownership: 101.16% [Q1] → 107.86% (+6.69%) [Q2]

0% more funds holding in top 10

Funds holding in top 10: 5 [Q1] → 5 (+0) [Q2]

3% less first-time investments, than exits

New positions opened: 29 | Existing positions closed: 30

3% less funds holding

Funds holding: 183 [Q1] → 177 (-6) [Q2]

Research analyst outlook

2 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $13 11% downside
• Avg. target: $17.50 20% upside
• High target: $22 51% upside

2 analyst ratings

• positive: 1 50%
• neutral: 1 50%
• negative: 0 0%

Citigroup Yigal Nochomovitz	51% upside $22	Buy Maintained	11 Aug 2025
HC Wainwright & Co. Robert Burns	11% downside $13	Neutral Reiterated	3 Jul 2025